133 related articles for article (PubMed ID: 15471217)
1. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
Lamers CH; Sleijfer S; Willemsen RA; Debets R; Kruit WH; Gratama JW; Stoter G
J Biol Regul Homeost Agents; 2004; 18(2):134-40. PubMed ID: 15471217
[TBL] [Abstract][Full Text] [Related]
2. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
Altenschmidt U; Klundt E; Groner B
J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
[TBL] [Abstract][Full Text] [Related]
4. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells.
Sasaki T; Ikeda H; Sato M; Ohkuri T; Abe H; Kuroki M; Onodera M; Miyamoto M; Kondo S; Nishimura T
Cancer Sci; 2006 Sep; 97(9):920-7. PubMed ID: 16856879
[TBL] [Abstract][Full Text] [Related]
6. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
7. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells.
Dall P; Herrmann I; Durst B; Stoff-Khalili MA; Bauerschmitz G; Hanstein B; Niederacher D
Cancer Immunol Immunother; 2005 Jan; 54(1):51-60. PubMed ID: 15693139
[TBL] [Abstract][Full Text] [Related]
8. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
9. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.
Bernhard H; Neudorfer J; Gebhard K; Conrad H; Hermann C; Nährig J; Fend F; Weber W; Busch DH; Peschel C
Cancer Immunol Immunother; 2008 Feb; 57(2):271-80. PubMed ID: 17646988
[TBL] [Abstract][Full Text] [Related]
10. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
[TBL] [Abstract][Full Text] [Related]
11. Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells.
Li J; Theofanous L; Stickel S; Bouton-Verville H; Burgin KE; Jakubchak S; Wagner TE; Wei Y
Int J Oncol; 2007 Jul; 31(1):193-7. PubMed ID: 17549421
[TBL] [Abstract][Full Text] [Related]
12. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
13. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
14. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
15. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
Li J; Mookerjee B; Wagner J
J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
[TBL] [Abstract][Full Text] [Related]
16. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
17. Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy.
Willemsen R; Chames P; Schooten E; Gratama JW; Debets R
Cytometry A; 2008 Nov; 73(11):1093-9. PubMed ID: 18785268
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
Westwood JA; Smyth MJ; Teng MW; Moeller M; Trapani JA; Scott AM; Smyth FE; Cartwright GA; Power BE; Hönemann D; Prince HM; Darcy PK; Kershaw MH
Proc Natl Acad Sci U S A; 2005 Dec; 102(52):19051-6. PubMed ID: 16365285
[TBL] [Abstract][Full Text] [Related]
19. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
20. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.
Weijtens ME; Willemsen RA; Valerio D; Stam K; Bolhuis RL
J Immunol; 1996 Jul; 157(2):836-43. PubMed ID: 8752936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
